<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180684</url>
  </required_header>
  <id_info>
    <org_study_id>HPV-201</org_study_id>
    <nct_id>NCT03180684</nct_id>
  </id_info>
  <brief_title>Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)</brief_title>
  <official_title>A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inovio Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inovio Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety and efficacy of an investigational
      immunotherapy VGX-3100, in combination with a study device, to treat women with vulvar HSIL
      (VIN 2 or VIN 3) associated with HPV types 16 and/or 18. VGX-3100 is being assessed as an
      alternative to surgery with the potential to clear the underlying HPV infection. For more
      information visit our study website at: www.VINresearchstudy.com
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 26, 2017</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples</measure>
    <time_frame>At Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Histologic Evidence of Vulvar HSIL</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Evidence of Vulvar HSIL, No Evidence of Vulvar Low Grade Squamous Intraepithelial Lesions (LSIL) (Vulvar Intraepithelial Neoplasia 1 [VIN1]), and No Evidence of Condyloma on Histology</measure>
    <time_frame>At Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with No Progression of Vulvar HSIL to Vulvar Cancer</measure>
    <time_frame>From baseline to Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction from Baseline in the Cumulative Surface Area of the Acetowhite Vulvar Lesion(s)</measure>
    <time_frame>From baseline to Weeks 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations</measure>
    <time_frame>From baseline to Weeks 15, 27, 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Interferon-Gamma Response Magnitude</measure>
    <time_frame>From baseline to Weeks 15, 27, 48, 74 and 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Flow Cytometry Response Magnitude</measure>
    <time_frame>At baseline and Week 27</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)</condition>
  <condition>Vulvar Dysplasia</condition>
  <condition>Vulvar Intraepithelial Neoplasia (VIN)</condition>
  <condition>VIN2</condition>
  <condition>VIN3</condition>
  <condition>Pre-cancerous Lesions of the Vulva</condition>
  <condition>Human Papillomavirus (HPV)</condition>
  <arm_group>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular (IM) injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injections with VGX-3100 followed by EP using the CELLECTRA™ 2000 device on Day 0, Week 4, Week 12 and Week 24. In addition, participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VGX-3100</intervention_name>
    <description>One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™ 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imiquimod 5% cream</intervention_name>
    <description>Participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.</description>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELLECTRA™ 2000</intervention_name>
    <description>IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 2000 device.</description>
    <arm_group_label>VGX-3100 + EP</arm_group_label>
    <arm_group_label>VGX-3100 + EP + Imiquimod</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18 and above;

          -  Have high grade squamous intraepithelial lesion (HSIL) of the vulva (VIN2 or VIN3)
             caused by infection with HPV types 16 and/or 18 confirmed at screening visit;

        Exclusion Criteria:

          -  Biopsy-proven differentiated VIN;

          -  Any previous treatment for vulvar HSIL within 4 weeks prior to screening;

          -  Allergy to imiquimod 5% cream or to an inactive ingredient in imiquimod 5% cream;

          -  Pregnant, breastfeeding or considering becoming pregnant within 6 months following the
             last dose of investigational product;

          -  Immunosuppression as a result of underlying illness or treatment;

          -  Significant acute or chronic medical illness.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prakash Bhuyan, MD</last_name>
    <role>Study Director</role>
    <affiliation>Inovio Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Christiana Care Health Systems</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Dominic Hospital</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers New Jersey</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lyndhurst Clinical Research</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complete HealthCare for Women, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Magee Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga's Program in Women's Oncology</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 6, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HPV-16</keyword>
  <keyword>HPV-18</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imiquimod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

